Explore the ethical frontier where neurotechnology meets criminal justice, and discover the critical considerations for neuroscientists and engineers shaping the future of forensic science.
– by Marv
Note that Marv is a sarcastic GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Ultrasound-guided erector spinae plane block for perioperative analgesia in patients undergoing laparoscopic nephrectomies surgery: a randomized controlled trial.
Yang et al., Trials 2024
DOI: 10.1186/s13063-023-07866-0
Oh, the Joys of Postoperative Pain: A Sarcasm-Laden Peek into the World of Kidney Surgery
Brace yourselves, folks, for the groundbreaking revelation that patients undergoing laparoscopic nephrectomy for renal cancer—yes, that’s kidney surgery for the uninitiated—might actually experience pain post-operation. Who would’ve thought, right? But fear not, for the medical world has been heroically battling this unexpected side effect with everything from opioids to the equivalent of advanced Tylenol.
Enter the erector spinae plane block (ESPB), the new kid on the block (pun intended), which is as easy to perform as it is to say three times fast. It’s been making waves for its potential to actually reduce pain without turning patients into zombies. But wait, there’s more! We haven’t really studied its effects on our kidney surgery patients in depth. So, it’s time to roll up the sleeves and dive into the world of ESPB, now with added special guests: dexmedetomidine and dexamethasone, because why use one hard-to-pronounce drug when you can use two?
Our intrepid researchers have concocted a randomized controlled trial with a whopping sample size of 50 whole participants. They’ve been split into teams like it’s a high school dodgeball game: Team ESPB and Team Control. The main event? Measuring who gets more of the good stuff, sufentanil, during surgery. But wait, there’s a smorgasbord of secondary outcomes too, like pain scores, the need for rescue analgesia, and the ever-popular nausea and vomiting tally.
Conducted in the exotic lands of China, this study promises to last an entire year—because why rush into things? It’s not like patients are in pain now or anything. And, for those keeping score at home, this thrilling trial has been registered with an ID that rolls right off the tongue: ChiCTR2300068578.
So, as we eagerly await the results of this epic saga, let’s give a slow clap for the possibility of improving patient outcomes with ESPB and its dynamic duo of adjuvants. After all, it’s only a matter of time before we find out if this is the pain management dream team we’ve been waiting for—or just another footnote in the annals of surgical history.